142 related articles for article (PubMed ID: 20564631)
1. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
Tong WG; Kantarjian H; O'Brien S; Faderl S; Ravandi F; Borthakur G; Shan J; Pierce S; Rios MB; Cortes J
Cancer; 2010 Jul; 116(13):3152-9. PubMed ID: 20564631
[TBL] [Abstract][Full Text] [Related]
2. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
Sasaki K; Lahoti A; Jabbour E; Jain P; Pierce S; Borthakur G; Daver N; Kadia T; Pemmaraju N; Ferrajoli A; O'Brien S; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):152-62. PubMed ID: 26796981
[TBL] [Abstract][Full Text] [Related]
3. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
Petzer AL; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Stanchev A; Grubinger T; Kwakkelstein M; Schuld P; Gastl G; Wolf D
Haematologica; 2012 Oct; 97(10):1562-9. PubMed ID: 22511495
[TBL] [Abstract][Full Text] [Related]
4. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Latagliata R; Ferrero D; Iurlo A; Cavazzini F; Castagnetti F; Abruzzese E; Fava C; Breccia M; Annunziata M; Stagno F; Tiribelli M; Binotto G; Mansueto G; Gozzini A; Russo S; Cavalli L; Montefusco E; Gugliotta G; Cedrone M; Russo Rossi A; Avanzini P; Pregno P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Storti S; D'Addosio A; Rege-Cambrin G; Luciano L; Alimena G
Drugs Aging; 2013 Aug; 30(8):629-37. PubMed ID: 23681399
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
[TBL] [Abstract][Full Text] [Related]
6. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.
Gafter-Gvili A; Leader A; Gurion R; Vidal L; Ram R; Shacham-Abulafia A; Ben-Bassat I; Lishner M; Shpilberg O; Raanani P
Am J Hematol; 2011 Aug; 86(8):657-62. PubMed ID: 21761431
[TBL] [Abstract][Full Text] [Related]
7. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
[TBL] [Abstract][Full Text] [Related]
8. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; O'Brien S; Jones D; Giles F; Garcia-Manero G; Faderl S; Ravandi F; Rios MB; Shan J; Cortes J
Blood; 2006 Sep; 108(6):1835-40. PubMed ID: 16709931
[TBL] [Abstract][Full Text] [Related]
9. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
10. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
[TBL] [Abstract][Full Text] [Related]
11. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Sneed TB; Kantarjian HM; Talpaz M; O'Brien S; Rios MB; Bekele BN; Zhou X; Resta D; Wierda W; Faderl S; Giles F; Cortes JE
Cancer; 2004 Jan; 100(1):116-21. PubMed ID: 14692031
[TBL] [Abstract][Full Text] [Related]
12. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
[TBL] [Abstract][Full Text] [Related]
13. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
Santos FP; Alvarado Y; Kantarjian H; Verma D; O'Brien S; Mattiuzzi G; Ravandi F; Borthakur G; Cortes J
Cancer; 2011 Mar; 117(5):982-91. PubMed ID: 20960502
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
[TBL] [Abstract][Full Text] [Related]
16. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Cheron N; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J; Guilhot F;
Blood; 2003 Dec; 102(13):4298-305. PubMed ID: 12933584
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure.
Onaka T; Takahashi N; Miura M; Yonezawa A; Imada K; Sawada K
Am J Hematol; 2012 Apr; 87(4):451. PubMed ID: 22407703
[No Abstract] [Full Text] [Related]
18. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Kantarjian H; Pasquini R; Lévy V; Jootar S; Holowiecki J; Hamerschlak N; Hughes T; Bleickardt E; Dejardin D; Cortes J; Shah NP
Cancer; 2009 Sep; 115(18):4136-47. PubMed ID: 19536906
[TBL] [Abstract][Full Text] [Related]
19. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
Haematologica; 2010 Aug; 95(8):1415-9. PubMed ID: 20305139
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study.
Morishima Y; Ogura M; Nishimura M; Yazaki F; Bessho M; Mizoguchi H; Chiba S; Hirai H; Tauchi T; Urabe A; Takahashi M; Ohnishi K; Yokozawa T; Emi N; Hirano M; Shimazaki C; Nakao S; Kawai Y; Fujimoto M; Taguchi H; Jinnai I; Ohno R
Int J Hematol; 2004 Oct; 80(3):261-6. PubMed ID: 15540902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
